日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease

针对相关问题的答复:α-突触核蛋白错误折叠抑制剂minzasolmin的体内效应支持其在帕金森病中的临床开发

Price, Diana L; Khan, Asma; Angers, Rachel; Cardenas, Alvaro; Prato, Maria Key; Bani, Massimo; Bonhaus, Douglas W; Citron, Martin; Biere, Anja-Leona

In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease

α-突触核蛋白错误折叠抑制剂 minzasolmin 的体内作用支持帕金森病的临床发展

Diana L Price, Asma Khan, Rachel Angers, Alvaro Cardenas, Maria Key Prato, Massimo Bani, Douglas W Bonhaus, Martin Citron, Anja-Leona Biere

The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease

小分子 α-突触核蛋白错误折叠抑制剂 NPT200-11 在帕金森病动物模型中产生多种益处

Diana L Price, Maya A Koike, Asma Khan, Wolfgang Wrasidlo, Edward Rockenstein, Eliezer Masliah, Douglas Bonhaus

A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease

针对 α-突触核蛋白的从头化合物可改善帕金森病模型中的缺陷

Wolfgang Wrasidlo, Igor F Tsigelny, Diana L Price, Garima Dutta, Edward Rockenstein, Thomas C Schwarz, Karin Ledolter, Douglas Bonhaus, Amy Paulino, Simona Eleuteri, Åge A Skjevik, Valentina L Kouznetsova, Brian Spencer, Paula Desplats, Tania Gonzalez-Ruelas, Margarita Trejo-Morales, Cassia R Overk,

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies

帕金森病/路易体痴呆转基因小鼠模型中视网膜 α-突触核蛋白::GFP 沉积物的纵向实时成像

Diana L Price, Edward Rockenstein, Michael Mante, Anthony Adame, Cassia Overk, Brian Spencer, Karen X Duong-Polk, Douglas Bonhaus, James Lindsey, Eliezer Masliah

Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase

奈匹卡司他(RS-25560-197)是一种新型、高效且选择性的多巴胺β-羟化酶抑制剂,其对儿茶酚胺的调节作用

Stanley, W C; Li, B; Bonhaus, D W; Johnson, L G; Lee, K; Porter, S; Walker, K; Martinez, G; Eglen, R M; Whiting, R L; Hegde, S S

The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro

RS 25259-197(一种强效且选择性的拮抗剂)与 5-HT3 受体的体外相互作用

Wong, E H; Clark, R; Leung, E; Loury, D; Bonhaus, D W; Jakeman, L; Parnes, H; Whiting, R L; Eglen, R M

Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo

体外和体内药理学表征两种新型高效5-HT4受体激动剂RS 67333和RS 67506

Eglen, R M; Bonhaus, D W; Johnson, L G; Leung, E; Clark, R D

Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat

功能性证据表明,药理学定义的α1A肾上腺素受体与克隆的α1C肾上腺素受体功能相等:大鼠离体灌注肾脏研究。

Blue, D R Jr; Bonhaus, D W; Ford, A P; Pfister, J R; Sharif, N A; Shieh, I A; Vimont, R L; Williams, T J; Clarke, D E

The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors

人类5-羟色胺2B(5-HT2B)受体基因产物的药理学和分布:与5-HT2A和5-HT2C受体的比较

Bonhaus, D W; Bach, C; DeSouza, A; Salazar, F H; Matsuoka, B D; Zuppan, P; Chan, H W; Eglen, R M